Abstract:Background Islet transplantation is used therapeutically in a minority of patients with type 1 diabetes (T1D). However, successful outcomes are hampered by early islet β-cell loss caused by immune rejection and autoimmunity. Recent studies have demonstrated that mesenchymal stromal cells can enhance islet function both in vitro and in vivo by secreting ligands that activate islet G-protein coupled receptors (GPCRs). Stromal cell-derived factor 1 (SDF-1) is an MSC-secreted GPCR ligand, whereas the suppressor of cytokine signaling 3 (SOCS3) is a negative regulator of STAT3-activating cytokines. Here, we determined whether improvement in islet function mediated by exogenous SDF-1 is impaired by SOCS3 in experimental models of T1D. Methods Isolated islets were cultured for 48 h with SDF-1. Cytokine-induced apoptosis was measured immediately. Islets from Socs3 −/− mice were pre-cultured with exogenous SDF-1 and transplanted underneath the kidney capsule of C57BL/6 mice with streptozotocin-induced diabetes. Blood glucose levels were monitored for 28 days. AMD3100, an antagonist of the SDF-1 ligand CXCR4, was administered subcutaneously to islet transplanted mice to inhibit CXCR4 before and after transplantation. Results SDF-1 protected islet cells from cytokine-induced apoptosis in vitro. SOCS3-knockout (KO) islets pretreated with SDF-1 were effective in reducing blood glucose in non-obese diabetic mice in vivo. We found that SDF-1 elicits localized immunosuppression in transplanted SOCS3-KO islets. Immunomodulation was observed when SOCS-KO islets were preconditioned with SDF-1. Gene expression and flow cytometric analyses revealed significantly decreased immune cell infiltration, inflammatory cytokines, and concomitant increases in FOXP3 + regulatory T cells, alternatively activated M2 macrophages, and dendritic cell phenotypes. Administration of AMD3100 impaired the SDF-1-mediated improvement in SOCS3-KO islet function and local immune suppression. Conclusion SDF-1 improves the function of islet grafts in autoimmune diabetes through regulation by CXCR4; however, the presence of SOCS3 reverses the protective effect of SDF-1 on islet grafts. These data reveal a molecular pathway that can elicit localized immunosuppression and delay graft destruction in transplanted islets.

MicroRNA-185 targets SOCS3 to inhibit beta-cell dysfunction in diabetes

MicroRNA-223 is Essential for Maintaining Functional Β-Cell Mass During Diabetes Through Inhibiting Both FOXO1 and SOX6 Pathways

Differentially Expressed MicroRNA-483 Confers Distinct Functions in Pancreatic Β- and Α-Cells

Retracted: MicroRNA‐30d Preserves Pancreatic Islet Β‐cell Function Through Negative Regulation of the JNK Signaling Pathway Via SOCS3 in Mice with Streptozotocin‐induced Diabetes Mellitus

SOCS3 Inhibits the Mesenchymal Stromal Cell Secretory Factor SDF-1-mediated Improvement of Islet Function in Non-Obese Diabetic Mice.

MicroRNA-15a Positively Regulates Insulin Synthesis by Inhibiting Uncoupling Protein-2 Expression

Circulating Mir-143-3p Inhibition Protects Against Insulin Resistance in Metabolic Syndrome Via Targeting of the Insulin-Like Growth Factor 2 Receptor.

[Mir-494-3p Reduces Insulin Sensitivity in Diabetic Cardiomyocytes by Down-Regulation of Insulin Receptor Substrate 1].

Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes

Effects of miR-22-3p targeted regulation of Socs3 on the hepatic insulin resistance in mice with gestational diabetes mellitus

MicroRNA-26a Regulates Insulin Sensitivity and Metabolism of Glucose and Lipids.

MicroRNA-494-3p Exacerbates Renal Epithelial Cell Dysfunction by Targeting SOCS6 under High Glucose Treatment

MicroRNA-185-5p inhibits hepatic gluconeogenesis and reduces fasting blood glucose levels by suppressing G6Pase

MiR-214 Promotes Renal Fibrosis in Diabetic Nephropathy Via Targeting SOCS1

Regulation of the Mir-19B-mediated SOCS6-JAK2/STAT3 Pathway by Lncrna MEG3 is Involved in High Glucose-Induced Apoptosis in Hrmecs.

MicroRNA-29c-3p Participates in Insulin Function to Modulate Polycystic Ovary Syndrome Via Targeting Forkhead Box O 3.

Dmso_a_335088 93..102

Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice

Expression level, clinical significance and target gene functions of circu-lating miR-103b in patients with pre-diabetes mellitus

Suppressors of cytokine signaling proteins and diabetes mellitus

Retraction Note: SOCS3 Inhibits Insulin Signaling in Porcine Primary Adipocytes.